Skip to main content
Top
Published in: AIDS and Behavior 11/2016

01-11-2016 | Original Paper

What Time is it? Adherence to Antiretroviral Therapy in Ethiopia

Authors: Yordanos M. Tiruneh, Ira B. Wilson

Published in: AIDS and Behavior | Issue 11/2016

Login to get access

Abstract

This study assessed adherence to antiretroviral therapy (ART) among people living with HIV/AIDS in Ethiopia and explored the sociocultural context in which they relate to their regimen requirements. Data were collected through semi-structured in-depth interviews with 105 patients on ART and observations held at the study clinic. We analyzed data using both qualitative and quantitative methods. Our findings indicate that study participants are highly adherent to dose but less adherent to dose schedule. Strict dose time instructions were reported as stressful and unrealistic. The discrepancy between adherence to dose and dose schedule could be explained by time perception, difficulty with the strictness of medication regimens, or beliefs about dose timing adherence. Care providers should acknowledge the complexities of medication practices and engage in shared decision-making to incorporate patients’ perspectives and identify effective interventions.
Literature
1.
go back to reference Mukherjee JS, Ivers L, Leandre F, Farmer P, Behforouz H. Antiretroviral therapy in resource-poor settings: decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr. 2006;43:S123–6.CrossRefPubMed Mukherjee JS, Ivers L, Leandre F, Farmer P, Behforouz H. Antiretroviral therapy in resource-poor settings: decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr. 2006;43:S123–6.CrossRefPubMed
2.
go back to reference Boyd MA, Cooper DA. Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS. 2007;21:S55–63.CrossRefPubMed Boyd MA, Cooper DA. Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS. 2007;21:S55–63.CrossRefPubMed
3.
go back to reference McNeil DG. Africans outdo US Patients in following AIDS therapy. New York Times. 2003. McNeil DG. Africans outdo US Patients in following AIDS therapy. New York Times. 2003.
4.
go back to reference Gill C, Hamer D, Simon J, Thea D, Sabin L. No room for complacency about adherence to antiretroviral therapy in Sub-saharan Africa. AIDS. 2005;19(12):1243–9.CrossRefPubMed Gill C, Hamer D, Simon J, Thea D, Sabin L. No room for complacency about adherence to antiretroviral therapy in Sub-saharan Africa. AIDS. 2005;19(12):1243–9.CrossRefPubMed
5.
go back to reference Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19:658–65.CrossRefPubMed Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19:658–65.CrossRefPubMed
6.
go back to reference Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, et al. Explaining adherence success in Sub-saharan Africa: an ethnographic study. Plos Med. 2009;6:39–47.CrossRef Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, et al. Explaining adherence success in Sub-saharan Africa: an ethnographic study. Plos Med. 2009;6:39–47.CrossRef
7.
go back to reference Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.CrossRefPubMed Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.CrossRefPubMed
8.
go back to reference Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med. 2000;50:1599–605.CrossRefPubMed Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med. 2000;50:1599–605.CrossRefPubMed
9.
go back to reference Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.CrossRefPubMed Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.CrossRefPubMed
10.
go back to reference Kalichman S, Cherry C, White D, Ml Jones, Grebler T, Kalichman M, et al. Sexual HIV transmission and antiretroviral therapy: a prospective cohort study of behavioral risk factors among men and women living with HIV/AIDS. Ann Behav Med. 2011;42(1):111–9.CrossRefPubMed Kalichman S, Cherry C, White D, Ml Jones, Grebler T, Kalichman M, et al. Sexual HIV transmission and antiretroviral therapy: a prospective cohort study of behavioral risk factors among men and women living with HIV/AIDS. Ann Behav Med. 2011;42(1):111–9.CrossRefPubMed
11.
go back to reference Lima VD, Harrigan R, Bangsberg, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (1999). 2009;50(5):529–36.CrossRef Lima VD, Harrigan R, Bangsberg, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (1999). 2009;50(5):529–36.CrossRef
12.
go back to reference Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, et al. Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223–31.CrossRefPubMed Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, et al. Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223–31.CrossRefPubMed
13.
go back to reference Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012;26(8):929–38.CrossRefPubMed Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012;26(8):929–38.CrossRefPubMed
14.
go back to reference Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. Plos Med. 2006;3:2039–64. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. Plos Med. 2006;3:2039–64.
15.
go back to reference Hawkins C, Murphy R. Adherence to antiretroviral therapy in resource-limited settings: everything matters. AIDS. 2007;21(8):1041–2.CrossRefPubMed Hawkins C, Murphy R. Adherence to antiretroviral therapy in resource-limited settings: everything matters. AIDS. 2007;21(8):1041–2.CrossRefPubMed
16.
go back to reference Kagee A, Remien RH, Berkman A, Hoffman S, Campos L, Swartz L. Structural barriers to ART adherence in Southern Africa: challenges and potential ways forward. Global Public Health. 2011;6:83–97.CrossRefPubMedPubMedCentral Kagee A, Remien RH, Berkman A, Hoffman S, Campos L, Swartz L. Structural barriers to ART adherence in Southern Africa: challenges and potential ways forward. Global Public Health. 2011;6:83–97.CrossRefPubMedPubMedCentral
17.
go back to reference Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor–based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564–73.CrossRefPubMed Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor–based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564–73.CrossRefPubMed
18.
go back to reference Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in Sub-saharan Africa and North America: a meta-analysis. J Am Med Assoc. 2006;296(6):679–90.CrossRef Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in Sub-saharan Africa and North America: a meta-analysis. J Am Med Assoc. 2006;296(6):679–90.CrossRef
19.
go back to reference Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to 3 years on treatment in Sub-saharan Africa, 2007–2009: systematic review. Tropical Med Int Health. 2010;15(s1):1–15.CrossRef Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to 3 years on treatment in Sub-saharan Africa, 2007–2009: systematic review. Tropical Med Int Health. 2010;15(s1):1–15.CrossRef
20.
go back to reference Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix M-L, Le Tiec C, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural Northwestern Uganda. BMC Infect Dis. 2009;9(1):81.CrossRefPubMedPubMedCentral Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix M-L, Le Tiec C, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural Northwestern Uganda. BMC Infect Dis. 2009;9(1):81.CrossRefPubMedPubMedCentral
21.
go back to reference Soria A, Porten K, Fampou-Toundji J-C, Galli L, Mougnutou R, Buard V, et al. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a cameroonian cohort of HIV type-1-infected patients. Antiviral Therapy. 2009;14:339–47.PubMed Soria A, Porten K, Fampou-Toundji J-C, Galli L, Mougnutou R, Buard V, et al. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a cameroonian cohort of HIV type-1-infected patients. Antiviral Therapy. 2009;14:339–47.PubMed
23.
go back to reference Johannessen A, Naman E, Kivuyo SL, Kasubi MJ, Holberg-Petersen M, Matee MI, et al. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis. 2009;9:108.CrossRefPubMedPubMedCentral Johannessen A, Naman E, Kivuyo SL, Kasubi MJ, Holberg-Petersen M, Matee MI, et al. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis. 2009;9:108.CrossRefPubMedPubMedCentral
24.
go back to reference Sankar AP, Nevedal DC, Neufeld S, Luborsky MR. What is a missed dose? Implications for construct validity and patient adherence. AIDS Care. 2007;19:775–80.CrossRefPubMedPubMedCentral Sankar AP, Nevedal DC, Neufeld S, Luborsky MR. What is a missed dose? Implications for construct validity and patient adherence. AIDS Care. 2007;19:775–80.CrossRefPubMedPubMedCentral
25.
go back to reference Reynolds NR. Adherence to antiretroviral therapies: state of the science. Curr HIV Res. 2004;2:207–14.CrossRefPubMed Reynolds NR. Adherence to antiretroviral therapies: state of the science. Curr HIV Res. 2004;2:207–14.CrossRefPubMed
26.
27.
go back to reference Schönnesson LN, Williams ML, Ross MW, Bratt G, Keel B. Factors associated with suboptimal antiretroviral therapy adherence to dose, schedule, and dietary instructions. AIDS Behav. 2007;11(2):175–83.CrossRef Schönnesson LN, Williams ML, Ross MW, Bratt G, Keel B. Factors associated with suboptimal antiretroviral therapy adherence to dose, schedule, and dietary instructions. AIDS Behav. 2007;11(2):175–83.CrossRef
28.
go back to reference Gill CJ, Sabin LL, Hamer DH, Keyi X, Jianbo Z, Li T, et al. Importance of dose timing to achieving undetectable viral loads. AIDS Behav. 2010;14(4):785–93.CrossRefPubMed Gill CJ, Sabin LL, Hamer DH, Keyi X, Jianbo Z, Li T, et al. Importance of dose timing to achieving undetectable viral loads. AIDS Behav. 2010;14(4):785–93.CrossRefPubMed
29.
go back to reference Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41(3):315–22.CrossRefPubMed Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41(3):315–22.CrossRefPubMed
30.
go back to reference Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12(1):86–94.CrossRefPubMed Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12(1):86–94.CrossRefPubMed
31.
go back to reference Genberg BL, Wilson IB, Bangsberg DR, Arnsten J, Goggin K, Remien RH, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26(11):1415–23.CrossRefPubMedPubMedCentral Genberg BL, Wilson IB, Bangsberg DR, Arnsten J, Goggin K, Remien RH, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26(11):1415–23.CrossRefPubMedPubMedCentral
32.
go back to reference Peltzer K, Preez N, Ramlagan S, Fomundam H. Use of traditional complementary and alternative medicine for HIV patients in Kwazulu-natal, South Africa. BMC Public Health. 2008;8:255.CrossRefPubMedPubMedCentral Peltzer K, Preez N, Ramlagan S, Fomundam H. Use of traditional complementary and alternative medicine for HIV patients in Kwazulu-natal, South Africa. BMC Public Health. 2008;8:255.CrossRefPubMedPubMedCentral
33.
go back to reference Ware N, Wyatt M, Tugenberg T. Social relationships, stigma and adherence to antiretroviral therapy for HIV/AIDS. AIDS Care. 2006;18:904–10.CrossRefPubMed Ware N, Wyatt M, Tugenberg T. Social relationships, stigma and adherence to antiretroviral therapy for HIV/AIDS. AIDS Care. 2006;18:904–10.CrossRefPubMed
34.
go back to reference Vervoort S, Borleffs J, Hoepelman A, Grypdonck M. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21:271–81.CrossRefPubMed Vervoort S, Borleffs J, Hoepelman A, Grypdonck M. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21:271–81.CrossRefPubMed
35.
go back to reference Goudge J, Ngoma B. Exploring antiretroviral treatment adherence in an urban setting in south africa. J Public Health Policy. 2011;32(S1):S52–64.CrossRefPubMed Goudge J, Ngoma B. Exploring antiretroviral treatment adherence in an urban setting in south africa. J Public Health Policy. 2011;32(S1):S52–64.CrossRefPubMed
36.
go back to reference Denison JA, Koole O, Tsui S, Menten J, Torpey K, van Praag E, et al. Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia. AIDS. 2015;29(3):361–71.CrossRefPubMedPubMedCentral Denison JA, Koole O, Tsui S, Menten J, Torpey K, van Praag E, et al. Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia. AIDS. 2015;29(3):361–71.CrossRefPubMedPubMedCentral
37.
go back to reference Merten S, Kenter E, McKenzie O, Musheke M, Ntalasha H, Martin-Hilber A. Patient-reported barriers and drivers of adherence to antiretrovirals in Sub-saharan Africa: a meta-ethnography. Trop Med Int Health. 2010;15:16–33.CrossRefPubMed Merten S, Kenter E, McKenzie O, Musheke M, Ntalasha H, Martin-Hilber A. Patient-reported barriers and drivers of adherence to antiretrovirals in Sub-saharan Africa: a meta-ethnography. Trop Med Int Health. 2010;15:16–33.CrossRefPubMed
38.
go back to reference Robinson JH, Callister LC, Berry JA, Dearing KA. Patient-centered care and adherence: definitions and applications to improve outcomes. J Am Acad Nurse Pract. 2008;20(12):600–7.CrossRefPubMed Robinson JH, Callister LC, Berry JA, Dearing KA. Patient-centered care and adherence: definitions and applications to improve outcomes. J Am Acad Nurse Pract. 2008;20(12):600–7.CrossRefPubMed
39.
go back to reference Govindasamy D, Meghij J, Negussi EK, Baggaley RC, Ford N, Kranzer K. Interventions to improve or facilitate linkage to or retention in pre-ART (HIV) care and initiation of ART in low- and middle-income settings—a systematic review. J Int AIDS Soc. 2014;17(1):19032.CrossRefPubMedPubMedCentral Govindasamy D, Meghij J, Negussi EK, Baggaley RC, Ford N, Kranzer K. Interventions to improve or facilitate linkage to or retention in pre-ART (HIV) care and initiation of ART in low- and middle-income settings—a systematic review. J Int AIDS Soc. 2014;17(1):19032.CrossRefPubMedPubMedCentral
40.
go back to reference Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Current Opin HIV AIDS. 2010;5:70–7.CrossRefPubMed Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Current Opin HIV AIDS. 2010;5:70–7.CrossRefPubMed
41.
go back to reference Sankar A, Golin C, Simoni J, Luborsky M, Pearson C, Natl Inst Drug A. How qualitative methods contribute to understanding combination antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2006;43:S54–68.CrossRefPubMedPubMedCentral Sankar A, Golin C, Simoni J, Luborsky M, Pearson C, Natl Inst Drug A. How qualitative methods contribute to understanding combination antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2006;43:S54–68.CrossRefPubMedPubMedCentral
42.
go back to reference Simoni J, Kurth A, Pearson C, Pantalone D, Merrill J, Frick P. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45.CrossRefPubMedPubMedCentral Simoni J, Kurth A, Pearson C, Pantalone D, Merrill J, Frick P. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45.CrossRefPubMedPubMedCentral
43.
go back to reference Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12:255–66.CrossRefPubMed Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12:255–66.CrossRefPubMed
44.
go back to reference Strauss A, Corbin J. Basics of qualitative research techniques and procedures for developing grounded theory. Thousand Oaks: Sage; 1998. Strauss A, Corbin J. Basics of qualitative research techniques and procedures for developing grounded theory. Thousand Oaks: Sage; 1998.
45.
go back to reference Mannheimer S, Thackeray L, Huppler Hullsiek K, Chesney M, Gardner EM, Wu AW, et al. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care. 2008;20(2):161–9.CrossRefPubMed Mannheimer S, Thackeray L, Huppler Hullsiek K, Chesney M, Gardner EM, Wu AW, et al. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care. 2008;20(2):161–9.CrossRefPubMed
46.
go back to reference Creswell J, Clark Plano V, Morales A. Qualitative research designs: selection and implementation. Couns Psychol. 2007;35:236–64.CrossRef Creswell J, Clark Plano V, Morales A. Qualitative research designs: selection and implementation. Couns Psychol. 2007;35:236–64.CrossRef
47.
go back to reference Glaser B, Strauss A. The discovery of grounded theory: strategies for qualitative research. New York: Aldine; 1967. Glaser B, Strauss A. The discovery of grounded theory: strategies for qualitative research. New York: Aldine; 1967.
48.
go back to reference Starks H, Brown Trinidad S. Choose your method: a comparison of phenomenology, discourse analysis, and grounded theory. Qual Health Res. 2007;17:1372–80.CrossRefPubMed Starks H, Brown Trinidad S. Choose your method: a comparison of phenomenology, discourse analysis, and grounded theory. Qual Health Res. 2007;17:1372–80.CrossRefPubMed
49.
go back to reference IBM. Statistical package for the social sciences (version 19.0). SPSS. Chicago: IBM; 2010. IBM. Statistical package for the social sciences (version 19.0). SPSS. Chicago: IBM; 2010.
50.
go back to reference Tadios Y, Davey G. Antiretroviral treatment adherence and its correlates in Addis Ababa, Ethiopia. Ethiop Med J. 2006;44:237–45.PubMed Tadios Y, Davey G. Antiretroviral treatment adherence and its correlates in Addis Ababa, Ethiopia. Ethiop Med J. 2006;44:237–45.PubMed
51.
go back to reference Tiyou A, Belachew T, Alemseged F, Biadgilign S. Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of Southwest Ethiopia. AIDS Res Therapy. 2010;7:39. doi:10.1186/1742-6405-7-39.CrossRef Tiyou A, Belachew T, Alemseged F, Biadgilign S. Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of Southwest Ethiopia. AIDS Res Therapy. 2010;7:39. doi:10.​1186/​1742-6405-7-39.CrossRef
52.
go back to reference Amberbir A, Woldemichael K, Getachew S. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health. 2008;8:265.CrossRefPubMedPubMedCentral Amberbir A, Woldemichael K, Getachew S. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health. 2008;8:265.CrossRefPubMedPubMedCentral
53.
go back to reference Chalker J, Andualem T, Minzi O, Ntaganira J, Ojoo A, Waako P, et al. Monitoring adherence and defaulting for antiretroviral therapy in 5 east African countries: an urgent need for standards. J Int Assoc Phys AIDS Care. 2008;7:193–9.CrossRef Chalker J, Andualem T, Minzi O, Ntaganira J, Ojoo A, Waako P, et al. Monitoring adherence and defaulting for antiretroviral therapy in 5 east African countries: an urgent need for standards. J Int Assoc Phys AIDS Care. 2008;7:193–9.CrossRef
54.
go back to reference McCoy L. Time, self and the medication day: a closer look at the everyday work of ‘adherence’. Sociol Health Illn. 2009;31:128–46.CrossRefPubMed McCoy L. Time, self and the medication day: a closer look at the everyday work of ‘adherence’. Sociol Health Illn. 2009;31:128–46.CrossRefPubMed
55.
56.
go back to reference Langebeek N, Gisolf EH, Reiss P, Vervoort SC, Hafsteinsdóttir TB, Richter C, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med. 2014;12:142.CrossRefPubMedPubMedCentral Langebeek N, Gisolf EH, Reiss P, Vervoort SC, Hafsteinsdóttir TB, Richter C, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med. 2014;12:142.CrossRefPubMedPubMedCentral
57.
go back to reference Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53:696–9.CrossRefPubMed Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53:696–9.CrossRefPubMed
58.
go back to reference Gourlay A, Wringe A, Birdthistle I, Mshana G, Michael D, Urassa M. “It is like that, we didn’t understand each other”: exploring the influence of patient-provider interactions on prevention of mother-to-child transmission of HIV service use in rural Tanzania. PLoS One. 2014;9(9):e106325.CrossRefPubMedPubMedCentral Gourlay A, Wringe A, Birdthistle I, Mshana G, Michael D, Urassa M. “It is like that, we didn’t understand each other”: exploring the influence of patient-provider interactions on prevention of mother-to-child transmission of HIV service use in rural Tanzania. PLoS One. 2014;9(9):e106325.CrossRefPubMedPubMedCentral
59.
go back to reference Assefa Y, Alebachew A, Lera M, Lynen L, Wouters E, Van Damme W. Scaling up antiretroviral treatment and improving patient retention in care: lessons from Ethiopia, 2005–2013. Glob Health. 2014;10:43. doi:10.1186/1744-8603-10-43.CrossRef Assefa Y, Alebachew A, Lera M, Lynen L, Wouters E, Van Damme W. Scaling up antiretroviral treatment and improving patient retention in care: lessons from Ethiopia, 2005–2013. Glob Health. 2014;10:43. doi:10.​1186/​1744-8603-10-43.CrossRef
60.
go back to reference WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO, 2013. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO, 2013.
61.
go back to reference Epstein RM. The science of patient-centered care. J Fam Pract. 2000;49(9):805–7.PubMed Epstein RM. The science of patient-centered care. J Fam Pract. 2000;49(9):805–7.PubMed
62.
go back to reference Charles C, Gafni A, Whelan T. Decision-making in the physician–patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med. 1999;49(5):651–61.CrossRefPubMed Charles C, Gafni A, Whelan T. Decision-making in the physician–patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med. 1999;49(5):651–61.CrossRefPubMed
63.
go back to reference Penn C, Watermeyer J, Evans M. Why don’t patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS. Patient Educ Couns. 2011;83(3):310–8.CrossRefPubMed Penn C, Watermeyer J, Evans M. Why don’t patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS. Patient Educ Couns. 2011;83(3):310–8.CrossRefPubMed
64.
go back to reference Sandman L, Granger BB, Ekman I, Munthe C. Adherence, shared decision-making and patient autonomy. Med Health Care Philos. 2012;15:115–27.CrossRefPubMed Sandman L, Granger BB, Ekman I, Munthe C. Adherence, shared decision-making and patient autonomy. Med Health Care Philos. 2012;15:115–27.CrossRefPubMed
65.
go back to reference Vermeire E, Hearnshaw H, Van Royen, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26:331–42.CrossRefPubMed Vermeire E, Hearnshaw H, Van Royen, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26:331–42.CrossRefPubMed
66.
go back to reference Wilson IB, Fowler FJ, Cosenza CA, Michaud J, Bentkover J, Rana A, et al. Cognitive and field testing of a new set of medication adherence self-report items for HIV care. AIDS Behav. 2014;18(12):2349–58.CrossRefPubMed Wilson IB, Fowler FJ, Cosenza CA, Michaud J, Bentkover J, Rana A, et al. Cognitive and field testing of a new set of medication adherence self-report items for HIV care. AIDS Behav. 2014;18(12):2349–58.CrossRefPubMed
67.
go back to reference Feldman BJ, Fredericksen RJ, Crane PK, Safren SA, Mugavero MJ, Willig JH, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav. 2013;17(1):307–18.CrossRefPubMedPubMedCentral Feldman BJ, Fredericksen RJ, Crane PK, Safren SA, Mugavero MJ, Willig JH, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav. 2013;17(1):307–18.CrossRefPubMedPubMedCentral
68.
go back to reference Creswell J. Qualitative inquiry and research design. Second edition. California: Sage; 2007. Creswell J. Qualitative inquiry and research design. Second edition. California: Sage; 2007.
Metadata
Title
What Time is it? Adherence to Antiretroviral Therapy in Ethiopia
Authors
Yordanos M. Tiruneh
Ira B. Wilson
Publication date
01-11-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 11/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1322-0

Other articles of this Issue 11/2016

AIDS and Behavior 11/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.